翻译英文医疗资料或有用信息

robertzhang

大家好，我母亲去年被诊断罹患肺ca。我也因此经常留意奇迹网。奇迹给了我很大的精神支持和甚至很多专业知识。虽然我远离父母也深知最后的治疗决定可能还得医生来下，但是奇迹网仍然可以帮助我少走弯路，对妈妈以后的治疗方向有大致的了解。
虽然我投入的时间很有限，但也希望能够做点什么，算是报答奇迹网吧。想了想也许我可以帮忙翻译这里的病友或家属所见的药品，医疗信息甚至最新的研究成果。如果有人需要，请尽管问，我会在业余时间尽量翻译。如果大家有什么别的建议我可以做到的，也请提出来。就算是我在做社工吧。

阿孟的妈妈

谢谢robertzhang，奇迹能走到今天，跟所有病友的齐心协力分不开的。你的帖子我帮你移到公益奇迹好么？

scd

齐心协力、互助互爱！

lvhuanran

robertzhang：您好！
对你的无私奉献精神非常敬佩，在这里我代表我个人先感谢你了。
下面是我得到的比较新的特罗凯维持用药的研究信息，请帮助翻译一下，以供病友们参考。谢谢了！

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Original TextDr Federico Cappuzzo MD a , Tudor Ciuleanu MD b, Lilia Stelmakh MD c, Prof Saulius Cicenas MD d, Aleksandra Szczésna MD e, Erzsébet Juhász MD f, Emilio Esteban MD g, Olivier Molinier MD h, Wolfram Brugger MD i, Ivan Melezínek MUDr CSc j, Gaëlle Klingelschmitt MSc k, Barbara Klughammer PhD l, Prof Giuseppe Giaccone MD m, on behalf of the SATURN investigators
Summary
Background
First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is usually limited to four to six cycles. Maintenance therapy can delay progression and prolong survival. The oral epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib has proven efficacy and tolerability in second-line NSCLC. We designed the phase 3, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study to assess use of erlotinib as maintenance therapy in patients with non-progressive disease following first-line platinum-doublet chemotherapy.
Methods
Between December, 2005, and May, 2008, 1949 patients were included in the run-in phase (four cycles of platinum-based chemotherapy). At the end of the run-in phase, 889 patients who did not have progressive disease were entered into the main study, and were randomly allocated using a 1:1 adaptive randomisation method through a third-party interactive voice response system to receive erlotinib (150 mg/day; n=438) or placebo (n=451) until progression or unacceptable toxicity. Patients were stratified by EGFR immunohistochemistry status, stage, Eastern Cooperative Oncology Group performance status, chemotherapy regimen, smoking history, and region. Co-primary endpoints were progression-free survival (PFS) in all analysable patients irrespective of EGFR status, and PFS in patients whose tumours had EGFR protein overexpression, as determined by immunohistochemistry. This study is registered with www.ClinicalTrials.gov, number NCT00556712.
Findings
884 patients were analysable for PFS; 437 in the erlotinib group and 447 in the placebo group. After a median follow-up of 11·4 months for the erlotinib group and 11·5 months for the placebo group, median PFS was significantly longer with erlotinib than with placebo: 12·3 weeks for patients in the erlotinib group versus 11·1 weeks for those in the placebo group (HR 0·71, 95% CI 0·62—0·82; p<0·0001). PFS was also significantly longer in patients with EGFR-positive immunohistochemistry who were treated with erlotinib (n=307) compared with EGFR-positive patients given placebo (n=311; median PFS 12·3 weeks in the erlotinib group vs 11·1 weeks in the placebo group; HR 0·69, 0·58—0·82; p<0·0001). The most common grade 3 or higher adverse events were rash (37 [9%] of 443 patients in the erlotinib group vs none of 445 in the placebo group) and diarrhoea (seven [2%] of 443 patients vs none of 445). Serious adverse events were reported in 47 patients (11%) on erlotinib compared with 34 patients (8%) on placebo. The most common serious adverse event was pneumonia (seven cases [2%] with erlotinib and four [<1%] with placebo).
Interpretation
Maintenance therapy with erlotinib for patients with NSCLC is well tolerated and significantly prolongs PFS compared with placebo. First-line maintenance with erlotinib could be considered in patients who do not progress after four cycles of chemotherapy.
Funding
F Hoffmann-La Roche Ltd.

阿孟的妈妈

http://www.51qiji.com/viewthread.php?tid=22264&page=1这里也有几篇，不知楼主是否有机会翻译一下？

双色小球

先在这里表示感谢！